SCIENTIFIC EVIDENCE

PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC-Mediated Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Wang WT, Duan ZW, Xing TY, Hua W, Du KX, Shang CY, Wu YF, Wang L, Li JY, Gao R, Liang JH, Xu W.

Publication Overview

Key findings, Countstar context, and access to the original paper.
2025
Bioprocessing
Cancer Research
No items found.
Key Finding
Notably, an orally bioavailable potent PTPN2/N1 active-site inhibitor ABBV-CLS-484 (AC484) demonstrates significant therapeutic potential against ALK + ALCL by disturbing mitochondrial renewal and blocking TFRC-mediated PINK1-PRKN-dependent mitophagy to exert anti-tumor activities, providing critical insights into the selection of targeted treatment strategies for ALK + ALCL patients and a strong rationale for advancing AC484 into clinical trials.
Countstar Connection
Within the research, Countstar (model not specified) assessed cell measurements in the study samples during growth assessment in the 2025 Advanced science study.
View paper ↗
Stay Connected toCountstar Science
Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.
Meet us online
Products
About Us
Contact
© 2026 Countstar. All rights reserved.